Infinity Supports Blood Cancer Awareness Month with Launch of Sparks of
Inspiration, a Campaign to Honor People Affected by Blood Cancer
CAMBRIDGE, Mass. -- September 3, 2013
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is observing National Blood
Cancer Awareness Month, joining patients, healthcare providers and patient
organizations in raising public awareness of blood cancers and the need for
continued research for novel treatment options. In support of patients and
their loved ones, Infinity is launching the Sparks of Inspiration campaign.
Throughout the month of September, Infinity encourages the submission of
stories along with photos or illustrations to honor friends, family members
and loved ones affected by blood cancer. For each submission received,
Infinity will make a donation of $10 to the Leukemia & Lymphoma Society (LLS),
the world's largest voluntary health organization dedicated to blood cancers.
To learn more about Sparks of Inspiration and submit your tribute, please
“We are grateful for the support from Infinity, which highlights our shared
goal of advancing new treatment options for patients affected by blood
cancers,” said John Walter, president and CEO of LLS. “Blood Cancer Awareness
Month is the right platform to create a sense of urgency about the need to
continue investing in lifesaving treatments and cures. As there are no means
of prevention of or early detection for most blood cancers, we must focus on
“Infinity is committed to discovering and developing new medicines for
patients with difficult-to-treat conditions, including blood cancers,”
commented Pedro Santabarbara, M.D., Ph.D. chief medical officer at Infinity.
“Through this campaign, we are honoring the courage and strength of patients
with blood cancers and their families. We are pleased to support the Leukemia
& Lymphoma Society’s mission of finding cures for blood cancers and improving
the quality of life for patients and families.”
Infinity is developing IPI-145, a potent, oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of
certain blood cancers.
“Early Phase 1 data of IPI-145 has shown encouraging signs of clinical
activity across a broad range of blood cancers. I am excited to be involved in
ongoing trials of IPI-145 and look forward to further evaluation of this
investigational drug,” said Ian Flinn, M.D., Ph.D., director, hematologic
malignancies program, Sarah Cannon Research Institute, and an investigator for
these clinical studies of IPI-145. “New targeted agents in development, such
as IPI-145, have the potential not only to expand therapeutic options for
patients but also to reduce or delay the need for chemotherapy.”
The company is currently enrolling patients in a Phase 2 study
(ClinicalTrials.gov Identifier NCT01882803) designed to evaluate the safety
and efficacy of its lead product candidate, IPI-145, for the treatment of
refractory indolent non-Hodgkin lymphoma (iNHL). Patients enrolled in this
study must have progressed within six months of receiving their last therapy.
Additionally, a Phase 1b investigator-sponsored trial of IPI-145 in patients
with B-cell NHL, chronic lymphocytic leukemia (CLL) and T-cell lymphoma in
combination with rituximab (a monoclonal antibody therapy), bendamustine (a
chemotherapy) or both rituximab and bendamustine is also open for enrollment
More About Sparks of Inspiration
Infinity encourages the submission of stories along with photos and
illustrations honoring friends, family members or loved ones affected by blood
cancer. For each submission received, Infinity will make a $10 donation to the
Leukemia & Lymphoma Society, up to a total of $5,000. Submissions can be made
through Infinity’s website www.infi.com. Submissions will be accepted from
September 3, 2013, through September 30, 2013.
About the Development of IPI-145 for the Treatment of Blood Cancers
Infinity is developing IPI-145, a potent, oral inhibitor of Class I
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The PI3Ks are a family
of enzymes involved in multiple cellular functions, including cell
proliferation and survival, cell differentiation, cell migration and
immunity.^1 The PI3K-delta and PI3K-gamma isoforms are preferentially
expressed in leukocytes (white blood cells), where they have distinct and
mostly non-overlapping roles in immune cell development and function.
Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to
develop differentiated therapies for the treatment of hematologic malignancies
as well as inflammatory diseases.
Infinity is currently enrolling patients with refractory indolent non-Hodgkin
lymphoma (iNHL) in a Phase 2 study to evaluate the safety and efficacy of
IPI-145 (ClinicalTrials.gov Identifier NCT01882803). An investigator-sponsored
Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and
T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy),
bendamustine (a chemotherapy) or both rituximab and bendamustine is also open
for enrollment (NCT01871675). Additionally, a Phase 1 study of IPI-145 in
patients with advanced hematologic malignancies is ongoing (NCT01476657).
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering,
developing and delivering best-in-class medicines to people with
difficult-to-treat diseases. Infinity combines proven scientific expertise
with a passion for developing novel small molecule drugs that target emerging
disease pathways. Infinity’s programs focused on the inhibition of
phosphoinositide-3-kinase and heat shock protein 90 are evidence of its
innovative approach to drug discovery and development. For more information on
Infinity, please refer to the company’s website at www.infi.com.
This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include, without limitation, statements regarding progress in
clinical trials of the company’s PI3K program and the therapeutic potential of
the company’s PI3K inhibitors. Important factors could cause actual results to
differ materially from these forward-looking statements, including market
conditions as well as risks and uncertainties associated with Infinity’s
business, including those risks and uncertainties described in greater detail
under the caption “Risk Factors” included in Infinity’s quarterly report on
Form 10-Q filed with theSecurities and Exchange Commission (SEC) onAugust 8,
2013, and other filings filed by Infinity with theSEC. Any forward-looking
statements contained in this press release speak only as of the date hereof,
and Infinity expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events or
^1 Weinberg RA (2007) Cytoplasmic signaling circuitry programs many of the
traits of cancer. In Jeffcock E, Zayatz E, and Mickey RK (Eds.) The biology of
cancer (pp. 179-183). New York, NY: Garland Science, Taylor & Francis Group.
Infinity Pharmaceuticals, Inc.
Jaren Irene Madden, 617-453-1336
Press spacebar to pause and continue. Press esc to stop.